Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States
HIV Medicine · 2026
DOI: 10.1111/hiv.70278 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift HIV Medicine, 2026. Verfasst von Adrian Khoei und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Dolutegravir, HIV Infections, HIV Integrase Inhibitors. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
Objectives
Dolutegravir (DTG) has been associated with weight gain in women with HIV, Black people with HIV and people with HIV60 years. This study aimed to characterise DTG population pharmacokinetics (PopPK) in a diverse population including these sub‐populations.
Methods
We conducted an intensive PK study nested within the Multicenter AIDS Cohort Study (MACS)/Women's Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS) and retrospectively quantified DTG plasma concentrations in historical specimens from participants in the WIHS and the MACS over several study visits. PopPK models were developed using NONMEM; covariate searches included relevant demographics and co‐medications.
Results
The analysis included 44 people with HIV from the MWCCS (56.8% women, 72.7% Black, 40.9% 60 years), 193 WIHS women (52.8% Black, 25.4% 60 years) and 137 MACS men (19.7% Black, 53.3% 60 years). A one‐compartment model with first‐order absorption and elimination and an absorption lag time (ALAG) best described DTG PK. Apparent clearance (CL/F) was 1.21, 1.26 and 0.95 L/h; apparent volume of distribution (V/F) was 21.2, 38.9 and 19.8 L, in the MWCCS, WIHS and MACS, respectively. For all three models, ALAG was 0.35 h. Sex, race and age were not statistically significant covariates. In the WIHS, lower total bilirubin and current cigarette smoking were significantly associated with higher CL/F, and higher body weight was significantly associated with higher V/F.
Conclusions
Our analysis did not support different DTG PK in women with HIV, Black people with HIV and people with HIV aged 60 years compared to other sub‐populations; causal analysis between DTG concentrations and weight gain over time are ongoing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Division of Infectious Diseases, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Maria L Alcaide, Cecile D Lahiri, Jack DeHovitz, Julie B Dumond
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- NCATS NIH HHS
- National Institutes of Health
- National Heart, Lung, and Blood Institute
Zitieren
APA
Khoei, A., Edmonds, A., Chang, Y., Ramirez, C., Vogan, M., Poliseno, A., Wolinsky, S., Ho, K., Brown, T. T., Margolick, J. B., Batson, J., Hoffmann, J., Marzinke, M. A., Kempf, M. C., Alcaide, M. L., Effoe, J., Lahiri, C. D., Ofotokun, I., Sheth, A. N., …, & Dumond, J. B. (2026). Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States. HIV Medicine. https://doi.org/10.1111/hiv.70278
Vancouver
Khoei A, Edmonds A, Chang Y, Ramirez C, Vogan M, Poliseno A, et al. Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States. HIV Medicine. 2026. doi:10.1111/hiv.70278
BibTeX
@article{Khoei2026,
author = {Khoei, Adrian and Edmonds, Andrew and Chang, Yen and Ramirez, Catalina and Vogan, Mackenzie and Poliseno, Amanda and Wolinsky, Steven and Ho, Ken and Brown, Todd T and Margolick, Joseph B and Batson, Jacquett and Hoffmann, Jennifer and Marzinke, Mark A and Kempf, Mirjam-Colette and Alcaide, Maria L and Effoe, Joffi and Lahiri, Cecile D and Ofotokun, Igho and Sheth, Anandi N and Gange, Stephen and French, Audrey L and Tamraz, Bani and Aouizerat, Bradley E and Tien, Phyllis C and Kassaye, Seble G and DeHovitz, Jack and Anastos, Kathryn and Chew, Kara W and Floris-Moore, Michelle and Dumond, Julie B},
title = {Dolutegravir population pharmacokinetics in racially, sex‐ and age‐diverse and antiretroviral therapy‐experienced adults with HIV in the United States},
journal = {HIV Medicine},
year = {2026},
doi = {10.1111/hiv.70278}
}
EUVIMED